New hope for Tough-to-Treat nasopharyngeal cancer: experimental drug shows promise in Late-Stage trial
NCT ID NCT06118333
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 386 adults with advanced nasopharyngeal cancer that has not responded to at least two prior treatments, including immunotherapy. The goal is to see if BL-B01D1 can shrink tumors and help people live longer. Participants are randomly assigned to receive either the new drug or the doctor's choice of chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.